Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as $67.16 and last traded at $67.16, with a volume of 192 shares trading hands. The stock had previously closed at $75.60.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on ZLDPF shares. Cantor Fitzgerald upgraded Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, January 21st. William Blair upgraded shares of Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.
View Our Latest Research Report on ZLDPF
Zealand Pharma A/S Stock Performance
The stock has a market cap of $4.40 billion, a price-to-earnings ratio of -26.25 and a beta of 0.81. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The firm has a fifty day moving average of $90.69 and a 200 day moving average of $103.54.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.19. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. The business had revenue of $1.30 million during the quarter, compared to the consensus estimate of $28.11 million. As a group, sell-side analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current year.
About Zealand Pharma A/S
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Further Reading
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
